Literature DB >> 9472662

High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis.

S Gasim1, A M Elhassan, E A Khalil, A Ismail, A M Kadaru, A Kharazmi, T G Theander.   

Abstract

Some patients develop post-kala-azar dermal leishmaniasis (PKDL) after they have been treated for the systemic infection kala-azar (visceral leishmaniasis). It has been an enigma why the parasites cause skin symptoms after the patients have been successfully treated for the systemic disease. We report here that PKDL development can be predicted before treatment of visceral leishmaniasis, and that IL-10 is involved in the pathogenesis. Before treatment of visceral leishmaniasis, Leishmania parasites were present in skin which appeared normal on all patients. However, IL-10 was detected in the keratinocytes and/or sweat glands of all patients who later developed PKDL (group 1) and not in any of the patients who did not develop PKDL (group 2). Furthermore, the levels of IL-10 in plasma as well as in peripheral blood mononuclear cell culture supernatants were higher in group 1 than in group 2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472662      PMCID: PMC1904865          DOI: 10.1046/j.1365-2249.1998.00468.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Diversity among Leishmania isolates from the Sudan: isoenzyme homogeneity of L. donovani versus heterogeneity of L. major.

Authors:  M E Ibrahim; D A Evans; T G Theander; A M el Hassan; A Kharazmi
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Jul-Aug       Impact factor: 2.184

2.  In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis.

Authors:  E Cillari; G Vitale; F Arcoleo; P D'Agostino; C Mocciaro; G Gambino; R Malta; G Stassi; C Giordano; S Milano
Journal:  Cytokine       Date:  1995-10       Impact factor: 3.861

3.  Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

Authors:  O Josimovic-Alasevic; H Feldmeier; K Zwingenberger; G Harms; H Hahn; M Shrisuphanunt; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

4.  Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.

Authors:  A M el Hassan; H W Ghalib; E E Zijlstra; I A Eltoum; M Satti; M S Ali; H M Ali
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 May-Jun       Impact factor: 2.184

5.  The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients.

Authors:  G Vitale; G Reina; S Mansueto; R Malta; G Gambino; C Mocciaro; R D'Agostino; M Dieli; E Cillari
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

6.  Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes.

Authors:  P A Bécherel; L Le Goff; S Ktorza; F Ouaaz; J M Mencia-Huerta; B Dugas; P Debré; M D Mossalayi; M Arock
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

7.  Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment.

Authors:  G S Nabors; J P Farrell
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

8.  Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.

Authors:  E E Zijlstra; A M el-Hassan; A Ismael
Journal:  Am J Trop Med Hyg       Date:  1995-04       Impact factor: 2.345

9.  Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections.

Authors:  A Gaafar; A Kharazmi; A Ismail; M Kemp; A Hey; C B Christensen; M Dafalla; A Y el Kadaro; A M el Hassan; T G Theander
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

10.  Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses.

Authors:  D J Berg; M W Leach; R Kühn; K Rajewsky; W Müller; N J Davidson; D Rennick
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

5.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

6.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

7.  Effects of CXCL10 on dendritic cell and CD4+ T-cell functions during Leishmania amazonensis infection.

Authors:  René E Vasquez; Lijun Xin; Lynn Soong
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

Review 8.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

9.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.